Strontium 89 (89Sr)
- Atc Codes:V10BX01#M05BX03
- CAS Codes:38270-90-5
- PHARMGKB ID:38270-90-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Dosage
- Special Considerations
Brand Names
Europe
Austria: Metastron; Bulgaria: Metastron; Cyprus: Metastron; Finland: Metastron; France: Metastron; Germany: Metastron; Greece: Metastron; Hungary: Metastron; Ireland: Metastron; Italy: Metastron; Netherlands: Metastron; Romania: Metastron; Poland: Metastron; Portugal: Metastron; Spain: Metastron; Sweden: Metastron.
North America
USA: Metastron, Strontium Chloride SR-89.
Asia
Japan: Metastron.
Drug combinations
Chemistry
Strontium (^89^Sr) Chloride: ^89^SrCl~2~. Mw: 159.90. CAS-38270-90-5 (1993).
Pharmacologic Category
Other Miscellaneous Therapeutic Agents. Radiopharmaceutical. (ATC-Code: V10BX01; M05BX03).
Mechanism of action
Therapeutic use
Relief of bone pain in skeletal metastases.
Pregnancy and lactiation implications
Contraindicated in pregnancy and lactation.
Unlabeled use
Contraindications
Hypersensitivity to any strontium-containing compounds or any other component of the formulation. Pregnancy. Breast-feeding.
Warnings and precautions
Should be handled with caution. A small number of patients experienced transient increase in bone pain at 36-72 hours postdose. Use with caution in bone marrow suppression, and in patients whose platelet counts fall <60000/mm^3^ or whose white blood cell counts fall <2400/mm^3^. Incontinent patients may require urinary catheterization. Use with caution in renal impairment (eliminated renally). Not indicated for use in cancer not involving bone.